<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02803749</url>
  </required_header>
  <id_info>
    <org_study_id>61141</org_study_id>
    <nct_id>NCT02803749</nct_id>
  </id_info>
  <brief_title>Buspirone in Parkinson's Disease</brief_title>
  <official_title>The Tolerability of Buspirone for the Treatment of Anxiety in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anxiety is highly prevalent in Parkinson's disease and negatively impacts quality of life yet
      it frequently remains untreated and there have been no clinical trials dedicated to
      evaluating the pharmacological treatment of anxiety in Parkinson's disease. Buspirone is
      effective for the treatment of generalized anxiety disorder in the general and elderly
      population. It is not known if it is effective for the treatment of anxiety in Parkinson's
      disease. This is a single-center, placebo-controlled, double-blind design with participants
      randomized with a 4:1 allocation ratio to flexible dosage buspirone (maximum dosage 30 mg
      twice daily) or placebo for 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">January 25, 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants Who Fail to Complete the 12-week Study on Study Drug.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Hamilton Anxiety Rating Scale (HAM-A) From Baseline to 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The HAM-A assess anxiety on 0-56 scale where a higher score represents a higher level of anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Responders (&gt;50% Reduction From Baseline or Reduction to ≤7 on HAM-A) at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The HAM-A assess anxiety on 0-56 scale where a higher score represents a higher level of anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of &quot;Much Improved&quot; or &quot;Very Much Improved&quot; on Patient Global Impressions-Improvement (PGI-I) at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The PGI-I assesses patient global impression of improvement on a 7-point scale where 1 = &quot;very much improved&quot; and 7 = &quot;very much worse.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Anxiety Using the Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>The HADS assesses anxiety on a scale of 0-21 and depression on a scale of 0-21 with higher scores indicating higher levels of anxiety and depression respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Unified Dyskinesia Rating Scale (UDysRS) From Baseline to 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The UDysRS assesses dyskinesias on a scale of 0-104 where a higher score represents more severe dyskinesias.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of &quot;Much Improved&quot; or &quot;Very Much Improved&quot; on Clinical Global Impressions-Improvement (CGI-I) at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The CGI-I assesses clinician global impression of improvement on a 7-point scale where 1 = &quot;very much improved&quot; and 7 = &quot;very much worse.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Hospital Anxiety and Depression Scale (HADS) - Depression From Baseline to 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The HADS assesses anxiety on a scale of 0-21 and depression on a scale of 0-21 with higher scores indicating higher levels of anxiety and depression respectively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Buspirone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Flexible dosage placebo for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buspirone</intervention_name>
    <arm_group_label>Buspirone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of idiopathic PD by UK Parkinson's Disease Society Brain Bank Clinical
             Diagnostic Criteria

          -  Significant anxiety as determined by the self-rated Parkinson Anxiety Scale (score ≥
             14)

          -  Able to provide written informed consent

          -  At least 18 years of age

        Exclusion Criteria:

          -  Diagnosis of atypical or secondary parkinsonism

          -  Concomitant treatment with an MAO inhibitor within the 14 days prior to screening
             visit

          -  Significant renal or hepatic impairment

          -  Significant cognitive impairment defined as MOCA score &lt; 23

          -  On-going depression with suicidal or homicidal ideation and concern for patient safety
             based on clinical determination by the investigator

          -  Allergy or intolerance to study drug, matching placebo, or their formulations

          -  History of prior exposure to study drug

          -  Lactating or pregnant woman

          -  Concomitant treatment with a disallowed medication (detailed in section 6.2)

          -  Active drug or alcohol use or dependence that, in the opinion of the investigator,
             would interfere with adherence to study requirements

          -  Concomitant treatment with an anxiolytic or antidepressant will be allowed however
             potential participants who had dosage changes in the 30 days prior to the screening
             visit will be excluded

          -  Use of an investigational drug within 30 days prior to screening visit

          -  Any medical or psychiatric comorbidity that, in the opinion of the investigator, would
             compromise study participation

          -  Dysphagia defined as a score of ≥ 2 on MDS-UPDRS Item 2.3 Chewing and Swallowing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Richard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <results_first_submitted>October 4, 2019</results_first_submitted>
  <results_first_submitted_qc>December 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 2, 2020</results_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Irene Richard</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buspirone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 27, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02803749/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 9, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02803749/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Buspirone</title>
          <description>Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
Buspirone</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Flexible dosage placebo for 12 weeks.
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Buspirone</title>
          <description>Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
Buspirone</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Flexible dosage placebo for 12 weeks.
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.5" spread="9.8"/>
                    <measurement group_id="B2" value="70.3" spread="10.6"/>
                    <measurement group_id="B3" value="66.4" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Married participants</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Greater than high school education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Depression</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Taking Antidepressant or Anxiolytic</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hoehn and Yahr Stage</title>
          <description>The Hoehn and Yahr scale defines broad categories of motor function in Parkinson's disease with a score of 1 indicating Unilateral involvement, a score of 2 indicating Bilateral involvement without balance impairment, a score of 3 indicating mild-moderate disability with balance impairment and a score of 4 indicating severe disability, still able to walk or stand unassisted.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MDS-UPDRS</title>
          <description>The Movement Disorder Society Unified Parkinson's Disease Rating scale evaluates aspects of motor and non-motor experiences of daily living. The scale assesses non-motor experiences of daily living (NM-EDL; range 0-52), motor experiences of daily living (M-EDL; range 0-52), motor examination ; range 0-132), and motor complications (range 0-24). Each subscale has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Scores for sub scales are summed to create the Total score. The total range of scores is 0-260. Higher scores mean worse outcomes.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.6" spread="22.5"/>
                    <measurement group_id="B2" value="67.5" spread="24.3"/>
                    <measurement group_id="B3" value="61.1" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nM-EDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.4" spread="5.2"/>
                    <measurement group_id="B2" value="13" spread="5.2"/>
                    <measurement group_id="B3" value="11.7" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-EDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.9" spread="7.6"/>
                    <measurement group_id="B2" value="14.5" spread="7.5"/>
                    <measurement group_id="B3" value="13.2" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Motor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.3" spread="15.3"/>
                    <measurement group_id="B2" value="37.5" spread="11.7"/>
                    <measurement group_id="B3" value="33.3" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Motor Compications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.0" spread="3.3"/>
                    <measurement group_id="B2" value="3.3" spread="3.5"/>
                    <measurement group_id="B3" value="3.1" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Unified Dyskinesia Rating Scale</title>
          <description>The Unified Dyskinesia Rating Scale captures the essential features of dyskinesia in Parkinson’s disease within a single scale, including patient perceptions, time factors, anatomical distribution, objective impairment, severity, and disability. A lower score is a better outcome for this measure.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="7.3"/>
                    <measurement group_id="B2" value="3.8" spread="5.2"/>
                    <measurement group_id="B3" value="5.0" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parkinson Anxiety Scale</title>
          <description>The Parkinson's Anxiety Scale measures the anxiety of Participants on a scale of 0-48 with a lower score being a better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.1" spread="3.9"/>
                    <measurement group_id="B2" value="19.3" spread="5.1"/>
                    <measurement group_id="B3" value="19.1" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton Anxiety Scale</title>
          <description>The Hamilton Anxiety Scale is used to measure the severity of anxiety symptoms. The scale ranges from 0-56 with a lower score being the desired outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.4" spread="4"/>
                    <measurement group_id="B2" value="12.3" spread="2.9"/>
                    <measurement group_id="B3" value="11.5" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hospital Anxiety and Depression Scale - Anxiety</title>
          <description>The Hospital Anxiety and Depression Scale is a fourteen item scale consisting of seven depression and seven anxiety questions. The scores range from 0-42 (for 14 questions) and 0-21 for each subsection of anxiety and depression. For the purposes of this information, anxiety and depression scores are split up with this data showing anxiety results so the scale ranges from 0-21 with a low score being better.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="3.1"/>
                    <measurement group_id="B2" value="6.8" spread="3.1"/>
                    <measurement group_id="B3" value="7.9" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hospital Anxiety and Depression Scale - Depression</title>
          <description>The Hospital Anxiety and Depression Scale is a fourteen item scale consisting of seven depression and seven anxiety questions. The scores range from 0-42 (for 14 questions) and 0-21 for each subsection of anxiety and depression For the purposes of this information, anxiety and depression scores are split up with this data showing depression results so the scale ranges from 0-21 with a low score being better.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" spread="3.1"/>
                    <measurement group_id="B2" value="4.8" spread="2.6"/>
                    <measurement group_id="B3" value="5.2" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montreal Cognitive Assessment</title>
          <description>The Montreal Cognitive Assessment (MoCA) measures cognitive capacity on a scale of 0-30 with a higher score being the better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.3" spread="2.3"/>
                    <measurement group_id="B2" value="26.8" spread="2.1"/>
                    <measurement group_id="B3" value="26.4" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Started Taking Antidepressant or Anxiolytic during Study</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants Who Fail to Complete the 12-week Study on Study Drug.</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buspirone</title>
            <description>Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
Buspirone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Flexible dosage placebo for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Fail to Complete the 12-week Study on Study Drug.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Hamilton Anxiety Rating Scale (HAM-A) From Baseline to 12 Weeks</title>
        <description>The HAM-A assess anxiety on 0-56 scale where a higher score represents a higher level of anxiety.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buspirone</title>
            <description>Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
Buspirone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Flexible dosage placebo for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Hamilton Anxiety Rating Scale (HAM-A) From Baseline to 12 Weeks</title>
          <description>The HAM-A assess anxiety on 0-56 scale where a higher score represents a higher level of anxiety.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.21" spread="1.13"/>
                    <measurement group_id="O2" value="-3.36" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Responders (&gt;50% Reduction From Baseline or Reduction to ≤7 on HAM-A) at 12 Weeks</title>
        <description>The HAM-A assess anxiety on 0-56 scale where a higher score represents a higher level of anxiety.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buspirone</title>
            <description>Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
Buspirone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Flexible dosage placebo for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responders (&gt;50% Reduction From Baseline or Reduction to ≤7 on HAM-A) at 12 Weeks</title>
          <description>The HAM-A assess anxiety on 0-56 scale where a higher score represents a higher level of anxiety.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of &quot;Much Improved&quot; or &quot;Very Much Improved&quot; on Patient Global Impressions-Improvement (PGI-I) at 12 Weeks</title>
        <description>The PGI-I assesses patient global impression of improvement on a 7-point scale where 1 = &quot;very much improved&quot; and 7 = &quot;very much worse.&quot;</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buspirone</title>
            <description>Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
Buspirone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Flexible dosage placebo for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of &quot;Much Improved&quot; or &quot;Very Much Improved&quot; on Patient Global Impressions-Improvement (PGI-I) at 12 Weeks</title>
          <description>The PGI-I assesses patient global impression of improvement on a 7-point scale where 1 = &quot;very much improved&quot; and 7 = &quot;very much worse.&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Anxiety Using the Hospital Anxiety and Depression Scale (HADS)</title>
        <description>The HADS assesses anxiety on a scale of 0-21 and depression on a scale of 0-21 with higher scores indicating higher levels of anxiety and depression respectively.</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buspirone</title>
            <description>Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
Buspirone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Flexible dosage placebo for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Anxiety Using the Hospital Anxiety and Depression Scale (HADS)</title>
          <description>The HADS assesses anxiety on a scale of 0-21 and depression on a scale of 0-21 with higher scores indicating higher levels of anxiety and depression respectively.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.87" spread="0.98"/>
                    <measurement group_id="O2" value="-0.89" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Unified Dyskinesia Rating Scale (UDysRS) From Baseline to 12 Weeks</title>
        <description>The UDysRS assesses dyskinesias on a scale of 0-104 where a higher score represents more severe dyskinesias.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buspirone</title>
            <description>Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
Buspirone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Flexible dosage placebo for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Unified Dyskinesia Rating Scale (UDysRS) From Baseline to 12 Weeks</title>
          <description>The UDysRS assesses dyskinesias on a scale of 0-104 where a higher score represents more severe dyskinesias.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".72" spread="3.22"/>
                    <measurement group_id="O2" value="7.78" spread="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of &quot;Much Improved&quot; or &quot;Very Much Improved&quot; on Clinical Global Impressions-Improvement (CGI-I) at 12 Weeks</title>
        <description>The CGI-I assesses clinician global impression of improvement on a 7-point scale where 1 = &quot;very much improved&quot; and 7 = &quot;very much worse.&quot;</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buspirone</title>
            <description>Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
Buspirone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Flexible dosage placebo for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of &quot;Much Improved&quot; or &quot;Very Much Improved&quot; on Clinical Global Impressions-Improvement (CGI-I) at 12 Weeks</title>
          <description>The CGI-I assesses clinician global impression of improvement on a 7-point scale where 1 = &quot;very much improved&quot; and 7 = &quot;very much worse.&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Hospital Anxiety and Depression Scale (HADS) - Depression From Baseline to 12 Weeks</title>
        <description>The HADS assesses anxiety on a scale of 0-21 and depression on a scale of 0-21 with higher scores indicating higher levels of anxiety and depression respectively.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buspirone</title>
            <description>Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
Buspirone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Flexible dosage placebo for 12 weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Hospital Anxiety and Depression Scale (HADS) - Depression From Baseline to 12 Weeks</title>
          <description>The HADS assesses anxiety on a scale of 0-21 and depression on a scale of 0-21 with higher scores indicating higher levels of anxiety and depression respectively.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.95" spread=".46"/>
                    <measurement group_id="O2" value=".34" spread=".81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Buspirone</title>
          <description>Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
Buspirone</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Flexible dosage placebo for 12 weeks.
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis/Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Increased freezing of gait</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>sleep difficulties</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>increased fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>increased tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>balance impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>increased peripheral edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gait Difficulties</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fuzziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hand Cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increased agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increased balance impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increased dystonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increased irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increased Knee pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increased OFF time</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>increased pain secondary to lipomas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Left shoulder/neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>leg pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>numbness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ruth Schneider</name_or_title>
      <organization>University of Rochester</organization>
      <phone>584-341-7500</phone>
      <email>ruth_schneider@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

